Immunotherapy or vaccine studies to date have primarily focused on the stimulation of CD8+ T cells and/or T helper (Th)-1 pro-inflammatory responses to biological targets expressed by tumor cells [20]. The gene discussed is CD8A; the disease is neoplasm.